losartan has been researched along with Arrhythmia in 24 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 7.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 7.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 5.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "There is increasing evidence that angiotensin II (Ang II) is associated with the occurrence of ventricular arrhythmias." | 3.74 | Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. ( Dong, F; Sheng, JW; Shi, CX; Wang, YH; Xu, YF, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion." | 3.71 | Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. ( Browne, AE; Chatterjee, K; Lee, RJ; Parmley, WW; Sievers, RE; Sun, Y; Zhu, B, 2001) |
| " Losartan increased the threshold for ventricular fibrillation (p=0." | 3.71 | The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke. ( Browne, AE; Chair, K; Chatterjee, K; Glantz, SA; Hillman, RT; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2002) |
| "EXP3174, but not losartan nor captopril, reduced the incidence of lethal ischemic ventricular arrhythmia in this preparation." | 3.70 | EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. ( Gould, RJ; Grossman, W; Kusma, SE; Lynch, JJ; Painter, CA; Stump, GL; Thomas, JM; Wallace, AA, 1999) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 3.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "The contribution of arrhythmias is unclear." | 1.48 | Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome. ( Crosson, JE; Czosek, RJ; Lacro, RV; Love, BA; Mah, DY; McCrindle, BW; Muiño-Mosquera, L; Olson, AK; Pilcher, TA; Shah, MJ; Sleeper, LA; Tierney, ESS; Wechsler, SB; Young, LT, 2018) |
| "Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart." | 1.36 | Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010) |
| "Total duration of arrhythmia (seconds) after I/R injury was similar in TGR and SD rats (433 +/- 109 vs." | 1.31 | Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. ( Crijns, HJ; de Boer, RA; Pinto, YM; Suurmeijer, AJ; van Geel, PP; van Gilst, WH; van Veldhuisen, DJ, 2002) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 1.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "The incidence of ventricular tachyarrhythmias during reperfusion was lower in the losartan group than in the control group (4/15 vs 6/15)." | 1.30 | Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. ( Annoura, M; Arakawa, K; Handa, K; Hiroki, T; Kumagai, K; Matsuo, K; Nakashima, Y; Yamanouchi, Y, 1997) |
| "Bradykinin acts as an endogenous cardioprotective substance because it suppresses ventricular dysrhythmias induced by ischemia." | 1.30 | Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins. ( Bolla, BS; de Guzman, FQ; Hussain, Y; Igić, R; Montiague, RR; Rabito, SF; Rajani, V, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mah, DY | 1 |
| Sleeper, LA | 1 |
| Crosson, JE | 1 |
| Czosek, RJ | 1 |
| Love, BA | 1 |
| McCrindle, BW | 1 |
| Muiño-Mosquera, L | 1 |
| Olson, AK | 1 |
| Pilcher, TA | 1 |
| Tierney, ESS | 1 |
| Shah, MJ | 1 |
| Wechsler, SB | 1 |
| Young, LT | 1 |
| Lacro, RV | 1 |
| Chiale, PA | 1 |
| Etcheverry, D | 1 |
| Pastori, JD | 1 |
| Garro, HA | 1 |
| Fernández, PA | 1 |
| González, MD | 1 |
| Elizari, MV | 1 |
| Bozbaş, SS | 1 |
| Bozbaş, H | 1 |
| Atar, A | 1 |
| Ulubay, G | 1 |
| Oner Eyüboğlu, F | 1 |
| Stein, M | 1 |
| Boulaksil, M | 1 |
| Jansen, JA | 1 |
| Herold, E | 1 |
| Noorman, M | 1 |
| Joles, JA | 1 |
| van Veen, TA | 1 |
| Houtman, MJ | 1 |
| Engelen, MA | 1 |
| Hauer, RN | 1 |
| de Bakker, JM | 1 |
| van Rijen, HV | 1 |
| Wachtell, K | 2 |
| Gerdts, E | 1 |
| Aurigemma, GP | 1 |
| Boman, K | 1 |
| Dahlöf, B | 3 |
| Nieminen, MS | 1 |
| Olsen, MH | 2 |
| Okin, PM | 2 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Devereux, RB | 2 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| Hille, DA | 1 |
| Edelman, JM | 2 |
| Safari, F | 1 |
| Hajizadeh, S | 1 |
| Shekarforoush, S | 1 |
| Bayat, G | 1 |
| Foadoddini, M | 1 |
| Khoshbaten, A | 1 |
| Oudot, A | 1 |
| Vergely, C | 1 |
| Ecarnot-Laubriet, A | 1 |
| Rochette, L | 1 |
| Lindholm, LH | 1 |
| Ibsen, H | 1 |
| Borch-Johnsen, K | 1 |
| Snapinn, S | 1 |
| Diener, HC | 1 |
| Pourdjabbar, A | 1 |
| Parker, TG | 1 |
| Desjardins, JF | 1 |
| Nguyen, QT | 1 |
| Tsoporis, JN | 1 |
| Lapointe, N | 1 |
| Rouleau, JL | 1 |
| Wang, YH | 1 |
| Shi, CX | 1 |
| Dong, F | 1 |
| Sheng, JW | 1 |
| Xu, YF | 1 |
| Matsuo, K | 1 |
| Kumagai, K | 1 |
| Annoura, M | 1 |
| Yamanouchi, Y | 1 |
| Handa, K | 1 |
| Nakashima, Y | 1 |
| Hiroki, T | 1 |
| Arakawa, K | 1 |
| Lee, YM | 1 |
| Peng, YY | 1 |
| Ding, YA | 1 |
| Yen, MH | 1 |
| Rajani, V | 1 |
| Hussain, Y | 1 |
| Bolla, BS | 1 |
| de Guzman, FQ | 1 |
| Montiague, RR | 1 |
| Igić, R | 1 |
| Rabito, SF | 1 |
| Hunyady, L | 1 |
| Nagy, L | 1 |
| Peczkowska, M | 1 |
| Kabat, M | 1 |
| Janaszek-Sitkowska, H | 1 |
| Lynch, JJ | 1 |
| Stump, GL | 1 |
| Wallace, AA | 1 |
| Painter, CA | 1 |
| Thomas, JM | 1 |
| Kusma, SE | 1 |
| Gould, RJ | 1 |
| Grossman, W | 1 |
| Gavras, I | 1 |
| Gavras, H | 1 |
| Zhu, B | 1 |
| Sun, Y | 1 |
| Sievers, RE | 2 |
| Browne, AE | 2 |
| Lee, RJ | 2 |
| Chatterjee, K | 2 |
| Parmley, WW | 2 |
| de Boer, RA | 1 |
| van Geel, PP | 1 |
| Pinto, YM | 1 |
| Suurmeijer, AJ | 1 |
| Crijns, HJ | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Zhu, BQ | 1 |
| Hillman, RT | 1 |
| Chair, K | 1 |
| Glantz, SA | 1 |
| Ozer, MK | 1 |
| Sahna, E | 1 |
| Birincioglu, M | 1 |
| Acet, A | 1 |
| Fleetwood, G | 1 |
| Boutinet, S | 1 |
| Meier, M | 1 |
| Wood, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Arrhythmia
| Article | Year |
|---|---|
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
[New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Cardiovascular Diseases; Clinical Tria | 1997 |
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardi | 2000 |
3 trials available for losartan and Arrhythmia
| Article | Year |
|---|---|
Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diastol | 2010 |
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Cardiovascular Diseases; Cause of Dea | 2010 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1997 |
19 other studies available for losartan and Arrhythmia
| Article | Year |
|---|---|
Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Arrhythmias | 2018 |
Clinical evaluation of losartan and diltiazem on the development of T-wave memory by right apical ventricular pacing.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardi | 2014 |
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr | 2010 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Heart; Heart Rate | 2012 |
Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Coronary Circulation; Enzyme Activation; Heart; In Vi | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pressure; Gene Express | 2005 |
Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Ca | 2008 |
Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac | 1997 |
Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Ar | 1997 |
Attenuation of epinephrine-induced dysrhythmias by bradykinin: role of nitric oxide and prostaglandins.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Car | 1997 |
EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhyt | 1999 |
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Disease Mode | 2001 |
Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Anti-Arrhythmia Agents; Ar | 2002 |
The renin-angiotensin system does not contribute to the endothelial dysfunction and increased infarct size in rats exposed to second hand smoke.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Electrocardiography; Endothe | 2002 |
Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia | 2002 |
Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
Topics: Animals; Arrhythmias, Cardiac; Creatine Kinase; Enalaprilat; Imidazoles; In Vitro Techniques; Losart | 1991 |